change control who
TRANSCRIPT
-
7/23/2019 Change Control WHO
1/62
Change Control
Luisa Stoppa
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Naning! the People"s #epu$lic of China %&'() Novem$er ())*
-
7/23/2019 Change Control WHO
2/62
-
7/23/2019 Change Control WHO
3/62
, |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Programme
To introduce the general elements on change control
To train ou in the guidelines !WH"#$%&' &()*S
guidelines' +,#$%&-
To become confident with S"&' forms and records of)hange )ontrol Sstem
To de.elop our inspection plan on change control
-
7/23/2019 Change Control WHO
4/62
- |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Principles of change control
/efore a medicinal product can be released' we need:
the manufacture and qualit control procedure should be
documented in the form of instructions0
The materials to be used must be specified0
The basic conditions required for a reproducible qualit'
efficac and safet must be defined !i1e1 suitable rooms'
qualified facilities' trained personnel' .alidatedprocedures' established specifications-
-
7/23/2019 Change Control WHO
5/62
. |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Principles of change control
/efore the requirements can be implemented' the suitabilit ofequipments*facilities and procedures must be pro.en withqualification * .alidation
This principle is not onl .alid the first time a medicinal product ismanufactured or the first time a facilit is used or a procedure
comes into effect
The principle applies to the whole histor of a medicinal product' aprocedure or a facilit and it is to be guaranteed
2s each requirement is stated in a document' it is clear that eachchange control for the requirements must also alwas in.ol.e adocumentation control
-
7/23/2019 Change Control WHO
6/62
( |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Principles of change control
+ach change to pre.iousl appro.ed requirementsrequires a re.iew and authori3ation to keep the sstem inits original state of pro.en suitabilit
4ormal change control guarantees that all changes aree.aluated for their effect on product qualit or .alidation
status
)hange control minimi3es the risk that changes can ha.eon the qualit or process characteristics
)hange control programs ha.e become recogni3ed asessential element of the pharmaceutical qualit assurancesstem
,he task
of
change
control
-
7/23/2019 Change Control WHO
7/62
/ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Principles of change control
(n the WH"#$%& guideline glossar there is definition ofthe term change control
Howe.er' the $%& guideline basicall contains onl fewnotes about the handling of changes
-
7/23/2019 Change Control WHO
8/620 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Principles of change control
(n the 2merican )ode of 4ederal 5egulation )45' the responsibilitfor the .erification and authori3ation of changes is task of the
qualit control unit
(n the +, regulations' the responsibilit is assigned to 6ualit ,nit
2s the change control is considered an essential element of the
pharmaceutical qualit assurance sstem' it is logical the personresponsible is qualit assurance !62 representati.e' 62 head-
-
7/23/2019 Change Control WHO
9/62+ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Principles of change control
)hange control is not department#specific' rather the taskof the whole compan
The change control monitors all tpes of changes which
can influence the process or product qualit and states
the measures necessar for implementing the change ordecides that a change should not be implemented
-
7/23/2019 Change Control WHO
10/62
-
7/23/2019 Change Control WHO
11/62'' |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Change control programs
%an tpes of changes affect se.eral areas at the sametime:
GMP re-uirements #egulator. re-uirements
Process securit. /validation0
Product -ualit. /specifications! approval0
1ffectiveness 2 safet. /approval0
Suita$le rooms and e-uipment /-ualification0
Suita$le personnel /training! e3perience0
-
7/23/2019 Change Control WHO
12/62
'2 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
2 central processing of change procedures' coordinatedb the qualit assurance department' has se.eral
ad.antages:
8 there is a common understanding of what a change represents0
8 the classification schemes used b the staff in.ol.ed to ratechanges are congruent0
8 the risk connected with the change can be e.aluated in a multi#
disciplinar manner0
8 there is uniform documentation and authori3ation procedure
Change control programs
-
7/23/2019 Change Control WHO
13/62
', |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
The tpe and scope of a change control program mustcompl with the requirements:
91 (n the classical $%rele.ant areas the change control
helpsto maintain the .alidated and established status1
alidated processes' qualified facilities' material
specifications can be influenced b changes and
medicinal products no longer compl with specifications
Change control programs
-
7/23/2019 Change Control WHO
14/62
'- |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
;1 Holder of marketing authori3ation must guarantee thatnecessar regulator pre#requisites are met1 )ontract
manufacturers that do not ha.e their own authori3ation
must guarantee that the contract gi.er is informed of
internal changes that could ha.e an influenceon theirapplication documentation !this requires that the contract
gi.er is included in the change control program of the
contract manufacturer-
Change control programs
-
7/23/2019 Change Control WHO
15/62
'. |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
-
7/23/2019 Change Control WHO
16/62
'( |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Change control programs
%an companies rate the changes requiring control
14'GMP
-
7/23/2019 Change Control WHO
17/62
-
7/23/2019 Change Control WHO
18/62
'0 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Change control programs
"therclassifications are
possible
-
7/23/2019 Change Control WHO
19/62
'+ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
(t is not decisi.e which and how man change#classes a compan has rated' but how it is
guaranteed that changes requiring control are
recogni3ed as such and implemented according
to a defined procedure
Change control programs
-
7/23/2019 Change Control WHO
20/62
2* |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
=ot all changes require a re.alidation
Change control programs
56+'GMP
-
7/23/2019 Change Control WHO
21/62
2' |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
(n the &()*S document &( >> !chapter 1@1A- there is a list ofchanges that ma require a re#.alidation:
Change control programs
-
7/23/2019 Change Control WHO
22/62
22 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
2lso in the WH"#$%& guidelines there is a list of changes thatma require a re#.alidation
Change control programs
-
7/23/2019 Change Control WHO
23/62
2, |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
WH"#$%& guidelines
Change control programs
-
7/23/2019 Change Control WHO
24/62
2- |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
&()*S document &(>>
Change control programs
-
7/23/2019 Change Control WHO
25/62
2. |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
The so called trials cause a problem in change control program1
Trials are preliminar' temporar changes which can permanentl
established or re.oked after a trial period
With trials' there is a risk that these intended temporar changes
graduall become permanent changes without a formal change
control procedure being carried out
How long a trial is retained and whether it is withdrawn after a trial
phase or be introduce permanentl' should be included in the
same procedure change control as all other changes
Change control programs
-
7/23/2019 Change Control WHO
26/62
2( |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Be.iations should not be treated as changes' not e.enwhen de.iations become changes after a failure hasbeen clarified
Be.iation is an unplanned and undesirable de.iation
from a requirement0 it occurs spontaneousl
Be.iations should be dealt with according a procedureabout handling de.iations
2ll .ariations implemented in emergenc !no planned' nocontrolled' no permanent- are included in de.iations
Change control programs
-
7/23/2019 Change Control WHO
27/62
2/ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Changes/planned changes0
Deviations/unplanned changes0
Su$mission of re-uest
'description of change
'rationale1valuation
'effect on validation status
'definition of revalidation measures
Approval
7mplementation of change
Closing
Notification
'description of deviation
1valuation
'effect on product -ualit.
'definition of corrective actions
'effect on validation status
'definition of revalidation measures
7mplementation of deviation
Closing
Change control programs
-
7/23/2019 Change Control WHO
28/62
-
7/23/2019 Change Control WHO
29/62
2+ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Change control programs
P7C2S guideline
-
7/23/2019 Change Control WHO
30/62
,* |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
2 problem is the issue of which changes the changecontrol team should dealt with
(t is ob.ious that this team cannot deal with all changes
in the compan
2s matter of fact' onl changes requiring control should
be processed b this team
Change control programs
-
7/23/2019 Change Control WHO
31/62
,' |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
4irstl' these are changes rele.ant for the regulatorstatus
Secondl' the are changes which could ha.e an
influences on the attributes of a $%rele.ant sstem'
facilit' equipment' material*product' procedure*process
The team should also deal with all changes whose grade
or implementation is unclear or questionable
Change control programs
-
7/23/2019 Change Control WHO
32/62
,2 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
How the team members communicate with each other?
=ot all changes require a meeting
(n cases which are eas to make a decision about' it can
be useful traditional paper#based circulation procedures'e#mail agreement or access to (ntranet#based forms
Change control programs
-
7/23/2019 Change Control WHO
33/62
,, |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
When a change control program has been introduced'the effecti.eness of the sstem can be re.iewed using
data which is eas to determine
Total number of changes request /year
Number of completed change requests / year
Change type / department involved
Duration of procedure: from application to closing
Number of deviations/year
Number of internal or external complaints /year
Number of OOS /year
Change control programs
-
7/23/2019 Change Control WHO
34/62
,- |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Change control programs
14'GMP
-
7/23/2019 Change Control WHO
35/62
,. |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange control requires a written procedureto establish at leastthe following steps:
hat type of changes does change control ta!e into account"
hat are the requirements for urgent changes"
#or $hich areas does this operating procedure apply"
ho can suggest changes"
%o$ are changes requested &forms' method of communication("
%o$ are changes graded and $ho is responsible for the rating"
%o$ are the measures for carrying out the change established"
ho is responsible for the implementation and monitoring of all measures"
ho is included in the change control team"
hat are the duties of the change control team"
%o$ is the change documented &format' content' storage("
ho is responsible to authori)e changes"
Documentation
-
7/23/2019 Change Control WHO
36/62
,( |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Documentation
)hange control requires a written procedure to establish at leastthe following steps:
-
7/23/2019 Change Control WHO
37/62
,/ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Documentation
)hange control requires a written procedure to establish at leastthe following steps:
-
7/23/2019 Change Control WHO
38/62
,0 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
2ll qualit#rele.ant changes should be documented
2ll actions to be taken' including the need for and e7tent
of qualification or .alidation' should be described
The records can be archi.ed in paper form orelectronicall
When storing documents' raw data and other rele.ant
documents for change should be kept accessible
Documentation
-
7/23/2019 Change Control WHO
39/62
,+ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hanges requiring control are generall documented inthe form of a change request in which the applicant for
the change proposes the tpe of change' suggests the
timeframes and measures for carring out the change
The change control team authori3es or not the change
The documentation for the change procedure should
show that the change was e.aluated !risk analsis-
Documentation
-
7/23/2019 Change Control WHO
40/62
-* |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Documentation
56+'GMP
-
7/23/2019 Change Control WHO
41/62
-' |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange controlprocedure
!e7ample 9-
Documentation
-
7/23/2019 Change Control WHO
42/62
-2 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange control procedure !e7ample ;' 9*;-
Documentation
-
7/23/2019 Change Control WHO
43/62
-
7/23/2019 Change Control WHO
44/62
-- |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange control procedure includes flow chartof thechange control process and the change request form
!or change form-
)hange request formrecords a request for change so
that each change is documented before it is appro.ed
The change request form includes the description of
the change' the benefits' costs' urgenc of the
change' change impact
Documentation
-
7/23/2019 Change Control WHO
45/62
-. |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange control procedure: flow chart !e7ample 9-
Documentation
-
7/23/2019 Change Control WHO
46/62
-( |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Documentation
)hange control procedure: flow chart !e7ample ;-
Change Request
Submission
Evaluation of
Change Impact
ValidationChangeRequest
Moreinformation
required
ChangeActivities
Change Closed
Approval
ActivitiesCompletion
ChangeActivities
Approval
ActivitiesCompletion
-
7/23/2019 Change Control WHO
47/62
-/ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Documentation
)hange control procedure: flow chart !e7ample
-
7/23/2019 Change Control WHO
48/62
-0 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange controlprocedure: flow
chart !e7ample A-
Documentation
CC8 9 change control $oard
-
7/23/2019 Change Control WHO
49/62
-+ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Documentation
)hange controlprocedure: flow
chart for change
master documents
!e7ample 9-
-
7/23/2019 Change Control WHO
50/62
.* |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange requestform !e7ample 9'
9*;-
Documentation
-
7/23/2019 Change Control WHO
51/62
.' |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange requestform !e7ample 9'
;*;-
Documentation
-
7/23/2019 Change Control WHO
52/62
.2 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange requestform !e7ample ;'
9*;-
Documentation
-
7/23/2019 Change Control WHO
53/62
., |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange requestform !e7ample ;'
;*;-
Documentation
-
7/23/2019 Change Control WHO
54/62
.- |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
)hange requestform !e7ample
-
7/23/2019 Change Control WHO
55/62
.. |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Documentation
)hange database:electronic cop
-
7/23/2019 Change Control WHO
56/62
.( |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Documentation
)hange control logbook
Change control logboo! &year:********(
Nb+ ,equestdate
,equester /department
-tem Description .pprovaldate
.ctions andtime limit
Closingdate
age:** of::::
0. 1anager signature ********* Date:::::::
f
-
7/23/2019 Change Control WHO
57/62
./ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
13amples of changes
)hanges to the cleaning procedure# use of a new cleaning agent
# change in concentration * .olumes of cleaning agent
# change in .olumes of rinsing water
# change of cleaning process parameters
)hanges to the production equipment
# changes to the )(& equipment
# changes to * replacement of equipment parts !difficult to give
detailed examples as these changes are too diverse-# change of process parameters
1 l f h
-
7/23/2019 Change Control WHO
58/62
.0 |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
13amples of changes
)hanges to the product# changes to composition !reformulation with different e7cipients-
# changes to the manufacturing process !i1e1 transfer of a product-
)hanges to H2) sstem * unidirectional flow
)hanges in la#out !i1e1 implementation of a pass#bo7-
7 ti l
-
7/23/2019 Change Control WHO
59/62
.+ |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
7nspection plan
To ask for the )hange )ontrol standard operatingprocedure
To check that all rele.ant steps for change control
implementation are detailed
To choose some applications !from the list in the logbook-
To .erif the applications and all requested documents
!change request form' in.estigation' request and closing
date-
C l i
-
7/23/2019 Change Control WHO
60/62
(* |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
Conclusion
The old adage sas: the onl thing constant is changeC
# f d t
-
7/23/2019 Change Control WHO
61/62
(' |
Manufacture of sterile medicines Advanced workshop for SFDA GMP inspectors
Nanin!" the People#s $epu%lic of &hina" '()2* Novem%er 2**+
#eference documents
WH" $%& guidelines 8 Technical 5eport series n1 D
-
7/23/2019 Change Control WHO
62/62
1orkshop on 13 pre4 alification re4 irements for reprod cti e health medicines
l;stoppa